• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

    3/10/25 3:00:00 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email

    Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

    IMC-M113V was well tolerated, with no dose-limiting toxicities

    Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH

    Enrollment in MAD portion of the trial continues with higher doses being evaluated

    (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, has today shared initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial of IMC-M113V, its functional cure candidate for human immunodeficiency virus (HIV).

    The data, presented in an oral session at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, in San Francisco, shows that IMC-M113V – the first T cell receptor bispecific therapy to target HIV in the clinic – is well tolerated and shows signals of dose-dependent viral control after antiretroviral treatment (ART) is interrupted. The MAD portion of the trial continues and is evaluating higher doses, to be followed by expansion cohorts at one or more doses.

    "I am encouraged by the safety profile and initial signals of anti-viral activity of IMC-M113V in the Phase 1/2 trial. It is uncommon to be able to interrupt ART for 12 weeks or longer, with the vast majority of people showing viral rebound by 4 weeks," said Dr. Beatriz Mothe, Associate Investigator, HIV Unit, Infectious Diseases Department, IrsiCaixa, Hospital Germans Trias i Pujol, Barcelona. "I look forward to further data from the trial at higher doses, as part of wider efforts to find solutions that could enable people with HIV to remain healthy without lifelong antiretroviral treatment."

    Initial MAD data

    The MAD portion of the Phase 1/2 dose escalation trial, reported at CROI, included 16 people living with HIV (PLWH) who were stable on ART. Enrollment excluded individuals who had started ART less than 12 weeks after acquiring HIV. While continuing ART, three sequential cohorts evaluated weekly IV infusions of IMC-M113V up to doses of 60 mcg (n=5), 120 mcg (n=5), and 300 mcg (n=6) administered over 12 weeks, followed by analytical treatment interruption (ATI) for up to 12 weeks, after which participants resumed their prior ART regimen.

    All doses were well tolerated and no serious adverse events (AEs) or dose limiting toxicities were observed. Mild (Grade 1) cytokine release syndrome, consisting of fever alone that resolved within 4 hours, was observed in five of the six PLWH in the 300 mcg cohort when receiving their first 300 mcg dose. There were no discontinuations due to AEs. One person withdrew prior to completing the dose schedule in the 300 mcg cohort for reasons unrelated to IMC-M113V.

    Dose-dependent increases in serum cytokines were observed, consistent with the mechanism of action, with the highest levels of T cell-derived cytokines at 300 mcg.

    In the 15 evaluable PLWH, delayed viral rebound and/or viremia control at any point during ATI was observed in 0 of 5 PLWH at 60 mcg, 1 of 5 at 120 mcg, and 2 of 5 at 300 mcg. The 3 PLWH with evidence of viral control had a viral load of approximately 200 c/mL at week 8. The historical rate for this observation is 5%1. Furthermore, 2 of these 3 PLWH remained off ART for the entire 12 week ATI period that was pre-specified in the protocol.

    In the 3 PLWH with evidence of viral control, the pattern consisted of initial viral rebound followed by viral reduction to approximately 200 c/mL, including 1 PLWH at 300 mcg who had initial viremia to >104 c/mL before subsequent decrease to <50 c/mL at week 12. This observation of initial viremia followed by control at week 12 is typically observed in <1% of all PLWH1. Such ‘regained' post-treatment control may be associated with an immune response to the virus.

    There was also a reduction in CD4+ T cell-associated HIV Gag RNA in some PLWH during treatment, indicating a reduction in the active virus reservoir, which was quantified at weeks 1, 7 and 13. A trend of reduction in intact HIV DNA was also observed post-treatment in a preliminary analysis of 6 people treated at the two highest doses.

    IMC-M113V and the STRIVE trial

    IMC-M113V utilizes a T cell receptor that binds to an HLA-A*02:01-Gag complex on HIV-infected immune cells. An anti-CD3 effector arm of the molecule then recruits T cells to destroy CD4+ cells containing integrated HIV DNA, known as the reservoir.

    The objectives of the first-in-human Soluble T cell Receptors in Viral Eradication (STRIVE) Phase 1/2 trial are to establish safe dose regimens administered alongside ART​ and to quantify antiviral activity, measured through post-treatment viral control (<200 c/ml) after ART withdrawal.

    The Company presented initial Phase 1 safety and pharmacodynamic activity data from the single-ascending dose portion of the trial in February 2023. The data demonstrated IMC-M113V was well tolerated with no serious adverse events. Expected markers of T cell activation were observed in half of people (n=10) who received a maximum dose of 15 mcg.

    ###

    About ImmTAV® molecules for infectious diseases

    ImmTAV (Immune mobilizing monoclonal TCRs Against Virus) molecules are novel bispecifics that are designed to enable the immune system to recognize and eliminate virally infected cells.

    Immunocore is advancing clinical candidates to achieve functional cure for patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients stop anti-retroviral therapy (ART), without the risk of virological relapse or onward transmission. This is known as ‘functional cure'. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with chronic HBV.

    About Immunocore

    Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company's most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "aim", "continue", "target" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the therapeutic potential of Immunocore's product candidates, including IMC-M113V; and expectations regarding the design, progress, timing, enrollment, randomization, scope, expansion, funding, and results of Immunocore's existing and planned clinical trials, including the IMC-M113V STRIVE Phase 1/2 clinical trial and expansions into additional cohorts. Any forward-looking statements are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company's business, financial position, strategy and anticipated milestones, including Immunocore's ability to conduct ongoing and planned clinical trials; Immunocore's ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products; Immunocore's ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore's ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore's ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore's need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore's ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore's current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore's filings with the Securities and Exchange Commission, including Immunocore's most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 26, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

    Contact Information

    Immunocore

    Sébastien Desprez, Head of Communications

    T: +44 (0) 7458030732

    E: [email protected]

    Follow on LinkedIn: @Immunocore

    Investor Relations

    Clayton Robertson / Morgan Warenius

    T: +1 (215) 384-4781

    E: [email protected]


    1 Gunst, J.D., Gohil, J., Li, J.Z. et al. Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. Nat Commun 16, 906 (2025).



    Primary Logo

    Get the next $IMCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    11/2/2023Overweight
    Cantor Fitzgerald
    10/31/2023$84.00Outperform
    Robert W. Baird
    More analyst ratings

    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to present at upcoming investor conferences

      Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April.                   Kempen Life Sciences Conference                  1x1 and small group meetings: Thursday, April 3, 2025                   Needham Virtual Healthcare Conferen

      4/2/25 8:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

      Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically impr

      3/10/25 3:00:00 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    SEC Filings

    See more
    • SEC Form S-8 filed by Immunocore Holdings plc

      S-8 - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 4:38:41 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:33:58 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Immunocore Holdings plc

      10-Q - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 7:00:46 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:28:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:22:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 6:40:08 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pao William

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:31:08 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pao William

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:29:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Financials

    Live finance-specific insights

    See more
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

      KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase

      2/26/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

      (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio u

      2/19/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immunocore downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

      12/13/24 8:04:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Mizuho with a new price target

      Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously

      11/11/24 7:41:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Immunocore with a new price target

      UBS initiated coverage of Immunocore with a rating of Sell and set a new price target of $24.00

      10/24/24 6:22:17 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunocore Appoints Siddharth Kaul to its Board of Directors

      Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

      6/9/22 7:45:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care